Industry

Immune-Onc’s antibody therapy collects second FDA orphan designation

The US Food and Drug Administration (FDA) has granted an orphan drug designation to Immune-Onc Therapeutics’ IO-202 for the treatment…

Yet another clinical hold for Gilead’s magrolimab trials

Gilead Sciences had paused enrolment in the magrolimab solid tumour trials, with the FDA requesting a partial clinical hold on…

Psychedelic treatments for mental health: Is there substance behind the hype?

Psychedelic treatments have been considered in the treatment of mental health since the 1950s, following Albert Hofmann’s development of lysergic…

Biotechs ride obesity drug wave with novel approaches that go beyond GLP-1RAs

The 2021 US approval of Novo Nordisk’s breakthrough therapy Wegovy (semaglutide) for obesity transformed the disease landscape, prompting companies to…

BioVaxys snatches up ‘bankrupt’ IMV’s preclinical and clinical assets

BioVaxys Technology has acquired the entire portfolio of discovery, preclinical and clinical assets along with the corresponding intellectual assets from…

Q4 2023 update: immuno-oncology related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that immuno-oncology accounted for 14 pharmaceutical deals announced in Q4 2023,…

Q4 2023 update: renewable energy related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that renewable energy accounted for 2 pharmaceutical deals announced in Q4…

Q4 2023 update: remote patient monitoring related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that remote patient monitoring accounted for 3 pharmaceutical deals announced in…

Q4 2023 update: electronic medical record (emr) systems related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that electronic medical record (emr) systems accounted for 2 pharmaceutical deals…

Q4 2023 update: microbiome related M&A activity in the pharmaceutical industry

Analysis of the key themes driving M&A activity reveals that microbiome accounted for 3 pharmaceutical deals announced in Q4 2023,…

close

Sign up to the newsletter: In Brief

Your corporate email address *
First name *
Last name *
Company name *
Job title *
Vist our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

Thank you for subscribing

View all newsletters from across the GlobalData Media network.

close